$DARE

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

Daré Bioscience (DARE) received a notice from Nasdaq on September 28, 2026, for failing to maintain a $1.00 minimum bid price for 30 consecutive days. The company has until March 29, 2027, to comply, with a possible 180-day extension if criteria are met.

Dare Bioscience (DARE) released a corporate presentation on October 1, 2026, for use in investor meetings. The presentation will be posted on the company's website under the Investors section. The information is furnished under Regulation FD Disclosure and is not incorporated into other SEC filings unless stated.

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules San Diego, August 14, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to

Daré Bioscience (NASDAQ: DARE) said it launched a strategic collaboration with MyMenopauseRx, a menopause-focused telehealth platform. MyMenopauseRx will be featured as a telehealth partner for DARE’s DARE to PLAY Sildenafil Cream, offering menopause specialist access and related care options via insurance or cash. Shares opened lower Tuesday.

Daré Bioscience (NASDAQ: DARE) said its vaginal probiotic Flora Sync LF5 is now available for order via its DARE Health Hub, marking the company’s first direct-to-consumer product revenue. The product is priced at $49 per box (6 capsules, 2 courses) and is non-prescription. Daré also cited ongoing Phase 2 DARE-HPV and Phase 3 Ovaprene progress.

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. dare-20260611 0001401914 FALSE 0001401914 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Daré Bioscience reported a Q1 2026 net loss of approximately $3 million on revenue of $152,455, primarily from R&D services and royalties. The company highlighted upcoming revenue milestones in 2026 and 2027 from product launches like Flora Sync LF5 and DARE to PLAY, while also advancing its pipeline with positive interim Phase 3 results for Ovaprene and ARPA-H funded DARE-HPV. Daré aims to build a multi-product revenue profile to complement its grant funding and equity financings.